Nuclear factor-kappaB (NF-κB) p50/RelA is a key molecule with a dual effect in the progression of ischemic stroke. In harmful ischemia, but not in preconditioning insult, neurotoxic activation of p50/RelA is characterized by RelA-specific acetylation at Lys310 (K310) and deacetylation at other Lys residues. The derangement of RelA acetylation is associated with activation of Bim promoter. Objective: With the aim of producing neuroprotection by correcting altered acetylation of RelA in brain ischemia, we combined the pharmacological inhibition of histone deacetylase (HDAC) 1-3, the enzymes known to reduce global RelA acetylation, and the activation of sirtuin 1, endowed with a specific deacetylase activity on the K310 residue of RelA. To afford this aim, we tested the clinically used HDAC 1-3 inhibitor entinostat (MS-275) and the sirtuin 1 activator resveratrol. Methods: We used the mouse model of transient middle cerebral artery occlusion (MCAO) and primary cortical neurons exposed to oxygen glucose deprivation (OGD). Results: The combined use of MS-275 and resveratrol, by restoring normal RelA acetylation, elicited a synergistic neuroprotection in neurons exposed to OGD. This effect correlated with MS-275 capability to increase total RelA acetylation and resveratrol capability to reduce RelA K310 acetylation through the activation of an AMPactivated protein kinase-sirtuin 1 pathway. The synergistic treatment reproduced the acetylation state of RelA peculiar of preconditioning ischemia. Neurons exposed to the combined drugs totally recovered the optimal histone H3 acetylation. Neuroprotection was reproduced in mice subjected to MCAO and treated with MS-275 (20 μg/kg and 200 μg/kg) or resveratrol (6800 μg/kg) individually. However, the administration of lowest doses of MS-275 (2 μg/kg) and resveratrol (68 μg/kg) synergistically reduced infarct volume and neurological deficits. Importantly, the treatment was effective even when administered 7 h after the stroke onset. Chromatin immunoprecipitation analysis of cortices harvested from treated mice showed that the RelA binding and histone acetylation increased at the Bcl-x L promoter and decreased at the Bim promoter. Conclusion: Our study reveals that epigenetic therapy shaping acetylation of both RelA and histones may be a promising strategy to limit post-ischemic injury with an extended therapeutic window.
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Introduction
Although advances in neurobiology outline a new era for brain restoration, total recovery of function following a stroke remains a rare accomplishment (Lloyd-Jones et al., 2010) . The only therapeutic agent actually approved is the recombinant tissue plasminogen activator (tPA) within 3 h of symptom onset; however, less than 5% of stroke patients can benefit from the thrombolytic approach (Fang et al., 2010; Lees et al., 2010) . Thus, identifying molecular targets for interventions that can be therapeutically implemented after stroke represents a compelling task for research in neurology. The mechanisms of neurodegeneration more involved in brain ischemia include excitotoxicity, calcium overload, Neurobiology of Disease 49 (2013) 177-189 Abbreviations: CBP, p300/CREB-binding protein; CSF, cerebrospinal fluid; DIV, days in vitro; LDH, lactate dehydrogenase; ip, intraperitoneal; K310, lysine 310; MCAO, middle cerebral artery occlusion; NF-κB, nuclear factor kappa B; OGD, oxygen glucose deprivation; SIRT1, sirtuin 1; HDAC, histone deacetylase; HAT, histone acetyltransferase; T172, threonine 172.
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